H. Lundbeck A/S (HLUBF)

Oppenheimer🏁 $TBPH Outperform/$27 $VTRS $HLUBF $HLBBF TAK $GSK AZN Oppenheimer said, We are launching on Theravance Biopharma at Outperform with a $27 PT. We see potential for the company's 1Q26 Phase 3 ampreloxetine readout to be transformative with a positive risk/reward into topline data. Our 50% PoS supports ~50% upside potential, and approval would likely support a roughly doubling of our valuation expectations. Downside risk is offset with Yupelri supporting the company at near cash flow breakeven, along with an anticipated pro forma cash balance after royalty milestones of ~$500M. Theravance shares have bid up over the past month (+26% vs. XBI's +5%) into Phase 3 data as we believe investors are taking notice of the transformative potential and mechanistic rationale, along with the downside protection. Positive Phase 3 data would likely support positive re-rating with $1B+ sales potential.

Cantor reiterated $DRUG at an Overweight rating ZGNX - $UCBJY LBPH - $HLUBF / $HLBBF Here's what Cantor had to say:

H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:

BTIG🏁 $DRUG Buy/$72. LBPH - $HLUBF/ $HLBBF $UCBJY $PRAX BTIG said in its initiation report: Bright Minds Biosciences ( $DRUG, Buy, $72 PT) is developing a very specific 5-HT2C agonist for epilepsies that is widely viewed as Longboard-like, but with key points of differentiation. BTIG added:

BTIG reit'd $TBPH Buy-$25/said it conts2view CYPRESS as sig derisked by preceding P3s— $TBPH utilized an external enrollment cmte =g same clinical neuro's for both Study 0170/CYPRESS, supporting pot for +VE readthru between the two trials. $ATHE $HLUBF $HLBBF $GSK AZN BTIG said:

H.C. Wainwright reiterated $DRUG Buy/$85. LBPH - $HLUBF/ $HLBBF $PRAX $JAZZ UCBJY UCBJF SNDX AVXL PHVS H.C. Wainwright said in its note:

$HLUBF - trending. https://www.macroaxis.com/target-price/HLUBF #stocks #earnings